PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.
Also called NCT07739537
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose other
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT07739537
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07739537. Allocation not applicable; no masking; primary purpose other. Start 2026-10-01 (anticipated); primary completion 2029-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
- Acronym
- PATHS-T2D
- Condition
- Diabete Type 2
- Condition
- Pharmacogenomic Drug Interaction
- Intervention (Drug)
- Orforglipron
- Lead sponsor
- Massachusetts General Hospital
Record details
- Record id
cardio:ct-nct07739537- Content hash
24a5ee46ab6e76de1bc9b131dd58b349ae62b0608e3aaca20a16a9f5caf3f268